Anika Therapeutics (ANIK) Cash from Investing Activities (2010 - 2026)

Anika Therapeutics (ANIK) has reported Cash from Investing Activities for 17 consecutive years, with -$1.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 137.48% year-over-year to -$1.3 million; the TTM figure through Jun 2026 stood at -$4.1 million (down 103.67% YoY), while the FY2025 annual figure was -$401000.0, up 95.19% from the prior year.
• Cash from Investing Activities declined to -$1.3 million in Q2 2026 per ANIK's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $1.7 million in Q1 2025 and bottomed at -$3.4 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$1.3 million across 5 years, with a median of -$1.4 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 176.47% — and 2025, when it soared 192.48%.
• Anika Therapeutics' Cash from Investing Activities stood at -$2.5 million in 2022, then rose by 27.24% to -$1.8 million in 2023, then advanced by 28.97% to -$1.3 million in 2024, then surged by 115.15% to $198000.0 in 2025, then sank by 746.46% to -$1.3 million in 2026.
• Business Quant data shows ANIK's Cash from Investing Activities at -$1.3 million in Q2 2026, -$1.2 million in Q1 2026, and $198000.0 in Q4 2025.